Business Context and Reporting Period
This Form 8-K Current Report was filed by TriSalus Life Sciences, Inc. on January 29, 2025. The filing reports the appointment of two new directors to the Board of Directors, expanding the Board size to 11 members.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The primary material change is the expansion of the Board of Directors and the appointment of:
- William Valle: Appointed as a Class I director (term expires at the 2027 annual meeting). He will serve on the Audit Committee and the Compensation Committee.
- Dr. Gary Gordon: Appointed as a Class III director (term expires at the 2026 annual meeting). He will serve on the Science and Technology Committee.
Compensation and Governance Details
Pursuant to the Company's compensation policy for non-employee directors, the following arrangements were established for the new appointees:
- Annual Cash Retainer: $50,000 for Board service.
- Committee Retainers:
- Mr. Valle: Additional $7,500 for the Audit Committee and $7,500 for the Compensation Committee.
- Dr. Gordon: Additional $7,500 for the Science and Technology Committee.
- Stock Options:
- Initial award: Option to purchase 35,000 shares, vesting annually over three years.
- Pro-rated annual grant: Option to purchase 6,250 shares, vesting on the earlier of the one-year anniversary or the next annual stockholder meeting.
- Future grants: Automatic annual option grants to purchase 15,000 shares on the date of each annual stockholder meeting.
Both directors will enter into the Company's standard Indemnification Agreement. The filing states there are no undisclosed transactions or understandings regarding their selection.
Investor Verification Checklist
- Verify the total number of outstanding shares and the potential dilution impact of the new stock option grants (41,250 shares per director initially).
- Confirm the vesting schedules and exercise prices of the granted options in the Company's equity incentive plan documents.
- Review the Company's cash position to ensure it can support the increased annual cash compensation for the expanded Board.
- Check for any subsequent filings regarding the composition of the Audit Committee to ensure compliance with Nasdaq listing standards.